🇺🇸 Rifaximin 550 MG in United States

10 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Acute Respiratory Failure — 1 report (10%)
  2. Agitation — 1 report (10%)
  3. Ascites — 1 report (10%)
  4. Asthenia — 1 report (10%)
  5. Blood Fibrinogen Decreased — 1 report (10%)
  6. Cardiac Arrest — 1 report (10%)
  7. Cardio-Respiratory Arrest — 1 report (10%)
  8. Cytokine Release Syndrome — 1 report (10%)
  9. Cytopenia — 1 report (10%)
  10. Deep Vein Thrombosis — 1 report (10%)

Source database →

Rifaximin 550 MG in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Rifaximin 550 MG approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Rifaximin 550 MG in United States?

Bonderup, Ole K., M.D. is the originator. The local marketing authorisation holder may differ — check the official source linked above.